First Time Loading...

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329

Watchlist Manager
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Logo
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Watchlist
Price: 34.99 CNY 3.46% Market Closed
Updated: May 3, 2024
Section:
 

Relative Value

The Relative Value of one Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd stock under the Base Case scenario is 47.58 CNY. Compared to the current market price of 34.99 CNY, Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is Undervalued by 26%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
47.58 CNY
Undervaluation 26%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.3
P/S
P/S
Price to Sales
3.3
vs History
15
vs Industry
36
Median 3Y
2.8
Median 5Y
2.6
Industry
2.4
Forward
2.9
More Details
27.3
P/E
P/E
Price to Earnings
27.3
vs History
17
vs Industry
18
Median 3Y
26
Median 5Y
22.8
Industry
22.9
Forward
21.9
More Details
39.1
P/OCF
P/OCF
Price to OCF
39.1
vs History
20
vs Industry
11
Median 3Y
33
Median 5Y
31.7
Industry
17.1
More Details
43.6
P/FCFE
P/FCFE
Price to FCFE
43.6
vs History
14
vs Industry
13
Median 3Y
32.6
Median 5Y
32.2
Industry
23.2
More Details
4.1
P/B
P/B
Price to Book Value
4.1
vs History
14
vs Industry
19
Median 3Y
3.5
Median 5Y
3
Industry
2.1
More Details
3.1
EV/S
EV/S
Enterprise Value to Sales
3.1
vs History
12
vs Industry
37
Median 3Y
2.7
Median 5Y
2.4
Industry
2.6
Forward
2.7
More Details
7.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.2
vs History
23
vs Industry
31
Median 3Y
6.6
Median 5Y
6.1
Industry
5.1
More Details
31.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
31.7
vs History
17
vs Industry
11
Median 3Y
29.4
Median 5Y
24.5
Industry
13.6
Forward
18.7
More Details
31.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
31.7
vs History
17
vs Industry
14
Median 3Y
29.4
Median 5Y
24.5
Industry
17
Forward
23.9
More Details
37.5
EV/OCF
EV/OCF
Enterprise Value to OCF
37.5
vs History
14
vs Industry
11
Median 3Y
30.6
Median 5Y
28.4
Industry
15.8
More Details
47.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
47.2
vs History
26
vs Industry
11
Median 3Y
39.2
Median 5Y
36.3
Industry
17.6
More Details
3.4
EV/IC
EV/IC
Enterprise Value to IC
3.4
vs History
19
vs Industry
25
Median 3Y
3
Median 5Y
2.7
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
26.9B CNY 3.3 27.3 31.7 31.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
699.8B USD 20.4 133.3 60.3 69.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.8T DKK 16.3 45.2 33 36
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
356.7B USD 4.4 8.8 11.7 15.5
US
Merck & Co Inc
NYSE:MRK
322.3B USD 5.2 139.7 33.3 52.8
UK
AstraZeneca PLC
LSE:AZN
186.4B GBP 5.1 39.2 140.6 225.6
CH
Novartis AG
SIX:NOVN
180.1B CHF 4.2 13.3 9.7 16.1
CH
Roche Holding AG
SIX:ROG
172.6B CHF 2.9 15 8.6 10.2
US
Pfizer Inc
NYSE:PFE
155.8B USD 2.7 73.5 11 16.2

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 133,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.